The Barbara Ann Karmanos Cancer Center in Detroit was recently selected to be one of 50 sites in the United States to offer the new U.S. Food and Drug Administration (FDA)-approved drug PROVENGE® (sipuleucel-T) to treat patients with advanced metastatic prostate cancer. PROVENGE, manufactured by Dendreon, is the first FDA-approved autologous cellular immunotherapy, a breakthrough treatment that uses the patient's own immune system to fight the prostate cancer... 
More...
More...